Aranda-Rivera AK, Cruz-Gregorio A, Arancibia-Hernndez YL, Hernndez-Cruz EY, Pedraza-Chaverri J
(2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Chao Liao, et al
(3) studies that did not include a control group
Do I Qualify 10% Average body weight reduction in 6 months* 8/10 Users say it feels more effective than past methods* 6" Average reduction in waist size reported by patients* 92% Users report maintaining their results with continued care* Why it's different More Included
For personalized guidance on managing your weight loss journey and potential medication interactions, consider taking our free assessment quiz to connect with our medical team